Clinical Trials
Quotient Sciences Constructs State-of-the-Art Early-Phase Formulation and Manufacturing Facility in U.S.
Quotient Sciences, a leading drug development services organization, announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot...
Clinical Trials
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an...
Clinical Trials
GamaMabs Pharma starts a phase 2 study of monoclonal antibody GM102 in patients with advanced or metastatic colorectal cancer
GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting the Anti-Müllerian Hormone Receptor II (AMHRII) for the treatment of cancer, announces that it has...
Clinical Trials
Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke
Thrombolytic Science, LLC (TSI) today announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of...
Clinical Trials
CRF Health Partners Innovative US Biotech with TrialMax® eCOA Solution for Phase III Prostate Oncology Study
CRF Health, the leading provider of patient-centered eSource technology solutions for the life sciences industry, announced that its TrialMax® Slate solution has been selected by...
Clinical Trials
Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients
Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, announced top line results of its Phase...
Clinical Trials
Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis
Servier, an independent international pharmaceutical company, and the company Galapagos NV announce the start of a global Phase 2 trial with S201086/GLPG1972 in knee osteoarthritis...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.